LeMaitre Vascular posts Q1 growth, lifts 2026 view

LeMaitre Vascular, Inc. reported strong preliminary Q1 2026 results with net sales of $66.6M, up from $59.9M, driven by 11% sales growth and broad strength across products and regions.

Rhea-AI Filing Summary

LeMaitre Vascular, Inc. reported strong preliminary Q1 2026 results with net sales of $66.6M, up from $59.9M, driven by 11% sales growth and broad strength across products and regions. Artegraft sales grew 36% worldwide, while grafts, valvulotomes, and carotid shunts each set record sales.

Gross margin reached 72.7%, up 350 basis points, and operating income rose to roughly $17.8M, a 41% increase. Diluted EPS grew 42% in Q1. Management’s guidance implies full-year 2026 sales growth of 12% and adjusted EPS growth of 26%, with Q2 sales expected around $71.5M at the midpoint.

The board approved a quarterly dividend of $0.25 per share payable on June 4, 2026, and authorized a share repurchase program of up to $100M through February 18, 2027. The company also highlighted non-GAAP metrics such as adjusted EBITDA and organic sales growth.

Positive

• Strong growth and margin expansion: Q1 2026 net sales rose to $66.6M from $59.9M with 11% sales growth, gross margin improved to 72.7% (+350 bps), operating income increased 41% to about $17.8M, and diluted EPS grew 42%, supported by broad product and geographic strength.
• Upbeat 2026 outlook and shareholder returns: Guidance implies 12% full‑year sales growth and 26% adjusted EPS growth, while the board approved a $0.25 quarterly dividend and authorized up to $100M of share repurchases through February 18, 2027.

Negative

• None.

Insights

Medical devices equity analyst

Q1 growth was double‑digit with higher margins and upbeat 2026 guidance.

LeMaitre Vascular delivered Q1 2026 net sales of $66.6M versus $59.9M, with strong product growth including Artegraft up 36% and record sales in grafts, valvulotomes, and carotid shunts. All three regions posted record revenue, led by EMEA up 20% and APAC up 18%.

Profitability expanded meaningfully. Gross margin improved to 72.7%, up 350 basis points, and operating income increased to about $17.8M, a 41% gain. Diluted EPS rose 42% year over year, while adjusted EBITDA increased 34%, reflecting operating leverage as operating expenses grew only 6%.

Guidance calls for Q2 2026 sales of $70.5M–$72.5M and full‑year sales of $277M–$283M, implying 12% organic growth, operating margin around 29%, and adjusted EPS growth of 26%. A $0.25 quarterly dividend and up to $100M share repurchase authorization add capital return alongside growth.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Q1 2026 net sales: $66.6M Gross margin: 72.7% Q1 2026 operating income: $17.8M +5 more

8 metrics

Q1 2026 net sales $66.6M Quarter ended March 31, 2026; up from $59.9M in Q1 2025

Gross margin 72.7% Q1 2026; 350 basis point improvement year over year

Q1 2026 operating income $17.8M Quarter ended March 31, 2026; +41% vs prior year

Q1 2026 diluted EPS $0.68 Quarter ended March 31, 2026; up from $0.48 in Q1 2025

Quarterly dividend $0.25/share Approved April 28, 2026; payable June 4, 2026

Share repurchase authorization $100.0M Board authorization on February 19, 2026; through February 18, 2027

2026 sales guidance midpoint $280.0M Full-year 2026 guidance; implies ~12% sales growth, 12% organic

2026 EPS guidance midpoint $3.00 Full-year 2026 projected earnings per share; 26% adjusted EPS growth

Key Terms

Adjusted EBITDA, organic sales, convertible senior notes, employee retention tax credit, +2 more

6 terms

Adjusted EBITDA financial

"Reconciliation between GAAP and Non-GAAP Adjusted EBITDA"

Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.

organic sales financial

"the Company has reported non-GAAP sales growth percentages after adjusting... The Company refers to the calculation... as “organic”"

Organic sales are the change in a company’s revenue that comes from its existing business operations, excluding effects of acquisitions, divestitures, and currency swings. Think of it like measuring how much a garden grows from the plants you already tended, rather than adding new pots; investors use organic sales to judge whether demand and core business performance are genuinely improving or if growth is driven by one‑time deals or accounting shifts.

convertible senior notes financial

"Convertible senior notes, net"

Convertible senior notes are a type of loan that a company issues to investors, which can be turned into company shares later on. They are called "senior" because they are paid back before other debts if the company runs into trouble. This allows investors to earn interest like a loan but also have the chance to own part of the company if its value rises.

employee retention tax credit financial

"exclude the effects of the employee retention tax credit received in 2025"

A government payroll tax credit that lets eligible employers offset or receive refunds for a portion of wages paid to keep employees on the payroll during qualifying disruptions. Think of it like a rebate or coupon on wage costs that improves short‑term cash flow and can show up as a one‑time boost to reported earnings or reduced payroll expenses. Investors watch it because claiming the credit affects company cash, profitability and signals how much government help a business used to retain workers.

non-GAAP financial measures financial

"Use of Non-GAAP Financial Measures LeMaitre management believes that... non-GAAP financial measures"

Non-GAAP financial measures are numbers companies use to show their financial performance that exclude certain expenses or income. They help investors see how the company might perform without one-time costs or other unusual items, giving a different perspective from official reports. However, since they can be adjusted, they don’t always tell the full story and should be looked at alongside standard financial figures.

operating leverage financial

"Full year 2026 shows op. leverage too - increased guidance implies 12% sales growth"

Operating leverage measures how much a company's profits are affected by changes in sales volume. When a business has high operating leverage, small increases in sales can lead to much larger increases in profit, much like a lever amplifies force. It matters to investors because it indicates how sensitive a company's earnings are to fluctuations in sales, affecting risk and potential returns.

Earnings Snapshot

Net sales: $66.6M · Guidance included

Q1 2026

Net sales $66.6M +11% vs Q1 2025

Gross margin 72.7% +350 bps YoY

Operating income $17.8M +41% YoY

Diluted EPS $0.68 +42% YoY

Guidance

2026 midpoint guidance: $280M net sales (~12% growth), $79.8M operating income, EPS $3.00 with 26% adjusted EPS growth.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How did LeMaitre Vascular (LMAT) perform in Q1 2026?

LeMaitre Vascular reported Q1 2026 net sales of $66.6 million, up from $59.9 million, reflecting 11% sales growth. Gross margin improved to 72.7%, operating income rose to about $17.8 million, and diluted EPS increased 42% compared with Q1 2025.

What guidance did LeMaitre Vascular (LMAT) provide for full-year 2026?

The company guided full-year 2026 sales to $277–$283 million, with a midpoint of $280 million, implying about 12% sales growth. It expects operating income around $79.8 million and midpoint EPS of $3.00, representing 26% adjusted EPS growth versus adjusted 2025.

What dividend did LeMaitre Vascular (LMAT) declare for shareholders?

LeMaitre’s board approved a quarterly dividend of $0.25 per share of common stock. The dividend is payable on June 4, 2026, to stockholders of record as of May 21, 2026, increasing cash returns compared with the prior-year quarterly dividend of $0.20.

Did LeMaitre Vascular (LMAT) announce a share repurchase program?

Yes. On February 19, 2026, the board authorized repurchases of up to $100 million of common stock. The program may be suspended or discontinued and is scheduled to conclude on February 18, 2027, unless the board decides to extend it further.

How did LeMaitre Vascular’s profitability metrics change in Q1 2026?

Q1 2026 gross margin rose to 72.7%, up 350 basis points. Operating income increased to roughly $17.8 million, up 41%, while adjusted EBITDA grew 34% to $20.3 million. These gains came as operating expenses increased only about 6% year over year.

What non-GAAP measures does LeMaitre Vascular (LMAT) emphasize?

LeMaitre highlights non-GAAP metrics such as adjusted EBITDA and organic sales growth, which adjust for currency and divestitures. It also provides adjusted operating income and adjusted EPS guidance excluding the 2025 employee retention tax credit, with detailed reconciliations to GAAP in its tables.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/05/2026 - 04:34 PM Learn about SEC filing dates

LEMAITRE VASCULAR INC false 0001158895 0001158895 2026-05-05 2026-05-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 5, 2026

LeMaitre Vascular, Inc.

(Exact name of registrant as specified in its charter)

Commission File Number: 001-33092

Delaware		04-2825458
(State or other jurisdiction of incorporation)		(IRS Employer Identification No.)

63 Second Avenue

Burlington, MA 01803

(Address of principal executive offices, including zip code)

781-221-2266

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class		Trading symbol		Name of exchange on which registered
Common stock, $0.01 par value per share		LMAT		The Nasdaq Global Market

Indicate by checkmark whether the company is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On May 5, 2026, LeMaitre Vascular, Inc. (the “Company”) issued a press release regarding its preliminary financial and operational results for the quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Report.

The information in this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Disclaimer on Forward-Looking Statements

This current report on Form 8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements regarding the Company’s business that are not historical facts may be “forward-looking statements” that involve risks and uncertainties. Forward-looking statements are based on management’s current, preliminary expectations and are subject to risks and uncertainties that could cause actual results to differ from the results predicted. These risks and uncertainties include risks and uncertainties included under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, as updated by its subsequent filings with the SEC, all of which are available on the Company’s investor relations website at http://www.lemaitre.com and on the SEC’s website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

Item 9.01. Financial Statements and Exhibits.

The following exhibits are furnished or filed as part of this Report, as applicable:

(d) Exhibits.

Exhibit No.		Description
99.1		Press release issued by LeMaitre Vascular, Inc. on May 5, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

Signature(s)

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						LeMaitre Vascular, Inc.
Date: May 5, 2026				By:		Dorian LeBlanc /s/ DORIAN LEBLANC
						Dorian LeBlanc Chief Financial Officer

Exhibit 99.1

LeMaitre Q1 2026 Financial Results

BURLINGTON, MA, May 5, 2026 – LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q1 2026 results, announced a quarterly dividend of $0.25/share, and provided guidance.

Q1 2026:

• Sales $66.6mm, +11% (+10% organic) vs. Q1 2025

• Gross margin 72.7% (+350 bps)

• Op. income $17.8mm (+41%)

• Op. margin 27%

• EPS $0.68 (+42%)

• Cash up $8.1mm sequentially to $367.2mm

Artegraft grew 36% worldwide in Q1, bolstered by its international launch. Grafts (+20%), valvulotomes (+15%), and carotid shunts (+11%) each posted record sales. The three geographies also posted records: EMEA (+20%), APAC (+18%), and the Americas (+7%).

Gross margin of 72.7% (+350 bps) increased due to higher pricing as well as manufacturing efficiencies. Q1 operating income of $17.8mm (+41%) also benefited from moderate operating expense growth (+6%).

Chairman/CEO George LeMaitre said, “Higher ASPs, geographic expansion and disciplined spending produced 11% sales growth and 42% EPS growth in Q1. Full year 2026 shows op. leverage too - increased guidance implies 12% sales growth and 26% (adjusted) EPS growth.”

Business Outlook

		Q2 2026 Guidance		Full Year Guidance
Sales		$70.5mm - $72.5mm (Mid $71.5mm, +11%, +11% org.)		$277mm - $283mm (Mid $280mm, +12%, +12% org.)
Gross Margin		72.1%		72.3%
Op. Income		$20.8mm - $22.3mm (Mid $21.6mm, +34%)		$77.6mm - $82.0mm (Mid $79.8mm, +18%, +24% adj.)
Op. Margin (Mid)		30%		29%
EPS		$0.79 - $0.84 (Mid $0.81, +35%.)		$2.93 - $3.08 (Mid $3.00, +19%, +26% adj.)

Quarterly Dividend

On April 28, 2026, the Company’s Board of Directors approved a quarterly dividend of $0.25/share of common stock. The dividend will be paid on June 4, 2026, to stockholders of record on May 21, 2026.

Share Repurchase Program

On February 19, 2026, the Company’s Board of Directors authorized the repurchase of up to $100.0mm of the Company’s common stock. The repurchase program may be suspended or discontinued at any time and will conclude on February 18, 2027, unless extended by the Board.

Conference Call Reminder

Management will conduct a conference call at 5:00pm ET today. The conference call will be broadcast live over the Internet. Individuals interested in listening to the webcast can log on to the Company’s website at www.lemaitre.com/investor. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. For individuals unable to join the live conference call, a replay will be available on the Company’s website.

A reconciliation of GAAP to non-GAAP results is included in the tables attached to this release.

About LeMaitre

LeMaitre is a provider of devices, implants, and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures, and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon.

LeMaitre is a registered trademark of LeMaitre Vascular, Inc. This press release may include other trademarks and trade names of the Company.

For more information about the Company, please visit www.lemaitre.com.

Use of Non-GAAP Financial Measures

LeMaitre management believes that in order to better understand the Company’s short- and long-term financial trends, investors may wish to consider certain non-GAAP financial measures as a supplement to financial performance measures prepared in accordance with GAAP. Non-GAAP financial measures are not based on a comprehensive set of accounting rules or principles and do not have standardized meanings. These non-GAAP measures result from facts and circumstances that may vary in frequency and/or impact on continuing operations. Non-GAAP measures should be considered in addition to, and not as a substitute for, GAAP financial performance measures. In addition to the description provided below, reconciliation of GAAP to non-GAAP results is provided in the financial statement tables included in this press release.

In this press release, the Company has reported non-GAAP sales growth percentages after adjusting for the impact of foreign currency exchange, business development transactions, and/or other events. The Company refers to the calculation of non-GAAP sales growth percentages as “organic” or “adjusted.” The Company analyzes non-GAAP sales on a constant currency basis, net of acquisitions and other non-recurring events. Because changes in foreign currency exchange rates have a non-operating impact on net sales, and acquisitions, divestitures, product discontinuations, factory closures, and other strategic transactions are episodic in nature and are highly variable to the reported sales results, the Company believes that evaluating growth in sales on a constant currency basis net of such transactions provides an additional and meaningful assessment of sales to management. Additionally, the Company has provided percentages for operating income and EPS guidance adjusted to exclude the effects of the employee retention tax credit received in 2025. Management believes that viewing projected growth in operating income and EPS excluding those effects provides an alternative and meaningful view of the Company’s projected profitability. The Company’s EPS guidance assumes no dilution from the Company’s convertible notes. Dilution from convertible notes is included in GAAP EPS if the average stock price during the period exceeds the conversion price and the effect is dilutive.

Investors are encouraged to review the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures set forth in the tables captioned “Reconciliation of GAAP to Non-GAAP Financial Measures” below.

Forward-Looking Statements

The Company’s current financial results, as discussed in this release, are preliminary and unaudited, and subject to adjustment. This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding the Company’s business that are not historical facts may be “forward-looking statements” that involve risks and uncertainties. Forward-looking statements are based on management’s current, preliminary expectations and are subject to risks and uncertainties that could cause actual results to differ from the results expected, including, but not limited to, our ability to maintain historic levels of profit growth; our ability to increase the selling prices of our products; competition from other medical device companies and alternative medical technologies; our ability to source, acquire, and integrate acquisitions; our dependence on sole- or limited-source suppliers; our ability to engage sales call points other than vascular surgeons; disruptions to our information technology systems or breaches of our information security systems; our implementation of our new enterprise resource planning system; our ability to procure, process, and preserve human tissue and comply with relevant regulatory requirements; the impact of a disruption in our manufacturing facilities; our ability to navigate the risks inherent in operating internationally; our ability to transition to direct sales models in certain international territories; the status of our regulatory approvals and compliance with regulatory requirements to market and sell our products both domestically and internationally; the occurrence of litigation relating to product liability, employment matters, intellectual property, contract disputes, and other matters; the occurrence of product defects or

recalls; our ability to service and repurchase our debt; the dilutive effect of a conversion of our debt; our ability to navigate executive officer transitions and retain key personnel; our ability to protect our intellectual property; volatility in the price of our common stock; and other risks and uncertainties included under the heading “Risk Factors” in our most recent Annual Report on Form 10-K, as updated by our subsequent filings with the SEC, which are all available on the Company’s investor relations website at http://www.lemaitre.com and on the SEC’s website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

CONTACT:

Gregory Manker

Director of Business Development and Investor Relations

+1 781-362-1260 x 419

gmanker@lemaitre.com

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)

CONDENSED CONSOLIDATED BALANCE SHEETS

(amounts in thousands)

		March 31, 2026				December 31, 2025
		(unaudited)
Assets
Current assets:
Cash and cash equivalents		$	26,851			$	28,244
Short-term marketable securities			340,382				330,876
Accounts receivable, net			35,770				33,610
Inventory and other deferred costs			70,820				70,422
Prepaid expenses and other current assets			3,998				5,080
Total current assets			477,821				468,232
Property and equipment, net			28,543				26,997
Right-of-use leased assets			19,832				15,762
Goodwill			65,945				65,945
Other intangibles, net			31,674				33,089
Deferred tax assets			741				759
Other assets			4,970				4,906
Total assets		$	629,526			$	615,690
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable		$	4,180			$	3,646
Accrued expenses			25,268				29,411
Acquisition-related obligations			475				322
Lease liabilities - short-term			3,446				2,944
Total current liabilities			33,369				36,323
Convertible senior notes, net			168,867				168,645
Lease liabilities - long-term			17,502				14,003
Deferred tax liabilities			1,855				1,735
Other long-term liabilities			1,311				1,468
Total liabilities			222,904				222,174
Stockholders’ equity
Common stock			245				244
Additional paid-in capital			233,450				228,407
Retained earnings			194,683				184,715
Accumulated other comprehensive loss			(3,857	)			(2,411	)
Treasury stock			(17,899	)			(17,439	)
Total stockholders’ equity			406,622				393,516
Total liabilities and stockholders’ equity		$	629,526			$	615,690

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

(amounts in thousands, except per share amounts)

(unaudited)

		For the three months ended
		March 31, 2026				March 31, 2025
Net sales		$	66,551			$	59,871
Cost of sales			18,155				18,451
Gross profit			48,396				41,420
Operating expenses:
Sales and marketing			14,515				14,212
General and administrative			12,046				10,487
Research and development			4,060				4,095
Total operating expenses			30,621				28,794
Income from operations			17,775				12,626
Other income (expense):
Investment income			3,324				2,903
Interest expense			(1,300	)			(1,290	)
Other income (loss), net			(127	)			2
Income before income taxes			19,672				14,241
Provision for income taxes			3,993				3,230
Net income		$	15,679			$	11,011
Earnings per share of common stock
Basic		$	0.69			$	0.49
Diluted		$	0.68			$	0.48
Weighted - average shares outstanding:
Basic			22,801				22,570
Diluted			23,031				22,899
Cash dividends declared per common share		$	0.25			$	0.20

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)

SELECTED NET SALES INFORMATION

(amounts in thousands)

(unaudited)

		For the three months ended
		March 31, 2026								March 31, 2025
		$				%				$				%
Net Sales by Geography
Americas		$	41,596				63	%		$	38,958				65	%
Europe, Middle East and Africa			20,287				30	%			16,959				28	%
Asia Pacific			4,668				7	%			3,954				7	%
Total Net Sales		$	66,551				100	%		$	59,871				100	%

LEMAITRE VASCULAR, INC (NASDAQ: LMAT)

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES

(amounts in thousands)

(unaudited)

		For the three months ended
		March 31, 2026				March 31, 2025
Reconciliation between GAAP and Non-GAAP Adjusted EBITDA
Net income as reported		$	15,679			$	11,011
Interest (income) expense, net			(2,024	)			(1,613	)
Amortization and depreciation expense			2,623				2,552
Provision for income taxes			3,993				3,230
Adjusted EBITDA		$	20,271			$	15,180
Adjusted EBITDA percentage increase			34	%

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES

(amounts in thousands)

(unaudited)

Reconciliation between GAAP and Non-GAAP sales growth:
For the three months ended March 31, 2026
Net sales as reported		$	66,551
Impact of currency exchange rate fluctuations			(2,048	)
Adjusted net sales						$	64,503
For the three months ended March 31, 2025
Net sales as reported		$	59,871
Net impact of divestitures excluding currency			(1,475	)
Adjusted net sales						$	58,396
Adjusted net sales increase for the three months ended March 31, 2026						$	6,107				10	%
Reconciliation between GAAP and Non-GAAP projected sales growth:
For the three months ending June 30, 2026
Net sales per guidance (midpoint)		$	71,500
Impact of currency exchange rate fluctuations			(680	)
Adjusted projected net sales						$	70,820
For the three months ended June 30, 2025
Net sales as reported		$	64,232
Net impact of divestitures excluding currency			(364	)
Adjusted net sales						$	63,868
Adjusted projected net sales increase for the three months ending June 30, 2026						$	6,952				11	%
Reconciliation between GAAP and Non-GAAP projected sales growth:
For the year ending December 31, 2026
Net sales per guidance (midpoint)		$	280,000
Impact of currency exchange rate fluctuations			(2,917	)
Adjusted projected net sales						$	277,083
For the year ended December 31, 2025
Net sales as reported		$	249,602
Net impact of divestitures excluding currency			(1,839	)
Adjusted net sales						$	247,763
Adjusted projected net sales increase for the year ending December 31, 2026						$	29,320				12	%
Reconciliation between GAAP and Non-GAAP projected operating income growth:
For the year ended December 31, 2026
Operating income per guidance (midpoint)		$	79,800
Projected operating income						$	79,800
For the year ended December 31, 2025
Operating income as reported		$	67,912
Impact of employee retention credit			(3,380	)
Adjusted operating income						$	64,532
Adjusted projected operating income increase for the year ending December 31, 2026						$	15,268				24	%
Reconciliation between GAAP and Non-GAAP earnings per share growth:
For the year ended December 31, 2026
Earnings per share per guidance (midpoint)		$	3.00
Projected earnings per share						$	3.00
For the year ended December 31, 2025
Earnings per share as reported		$	2.52
Impact of employee retention credit			(0.14	)
Adjusted earnings per share						$	2.38
Adjusted projected earnings per share increase for the year ending December 31, 2026						$	0.62				26	%

Filing Exhibits & Attachments

4 documents

Press Releases

• EX-99.1 EX-99.1 132.4 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.1 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 16.8 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 10.6 KB